Andrea Salmaggi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/921356/publications.pdf

Version: 2024-02-01

250 papers

6,589 citations

87723 38 h-index 98622 67 g-index

257 all docs

257 docs citations

times ranked

257

9027 citing authors

#	Article	IF	CITATIONS
1	Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype. American Journal of Human Genetics, 2002, 71, 656-662.	2.6	611
2	Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 2006, 54, 850-860.	2.5	246
3	Impaired Differentiation of Osteoclasts in TREM-2–deficient Individuals. Journal of Experimental Medicine, 2003, 198, 645-651.	4.2	208
4	Expression of Drug Resistance Proteins Pgp, MRP1, MRP3, MRP5 AND GST-Ï€ in Human Glioma. Journal of Neuro-Oncology, 2005, 74, 113-121.	1.4	187
5	Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain, 2008, 131, 2321-2331.	3.7	169
6	Validation of Italian multiple sclerosis quality of life 54 questionnaire. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 158-162.	0.9	149
7	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. Journal of Neuro-Oncology, 2003, 62, 297-303.	1.4	131
8	Endothelium and the brain in CNS lupus. Lupus, 2003, 12, 919-928.	0.8	102
9	Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma. Clinical Cancer Research, 2004, 10, 1312-1317.	3.2	90
10	Hereditary Cerebral Hemorrhage With Amyloidosis Associated With the E693K Mutation of APP. Archives of Neurology, 2010, 67, 987-95.	4.9	87
11	CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biology and Therapy, 2009, 8, 1608-1614.	1.5	83
12	Natural history and management of brainstem gliomas in adults. Journal of Neurology, 2008, 255, 171-177.	1.8	82
13	Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute Relapses. European Neurology, 1994, 34, 199-203.	0.6	80
14	A phase l–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer, 2009, 100, 28-36.	2.9	76
15	Immediate and Sustained Effects of 5-Day Transcranial Direct Current Stimulation of the Motor Cortex in Phantom Limb Pain. Journal of Pain, 2015, 16, 657-665.	0.7	75
16	CXCL12 in Malignant Glial Tumors: A Possible Role in Angiogenesis and Cross-Talk between Endothelial and Tumoral Cells. Journal of Neuro-Oncology, 2004, 67, 305-317.	1.4	72
17	Expression and Modulation of IFN-Î ³ -Inducible Chemokines (IP-10, Mig, and I-TAC) in Human Brain Endothelium and Astrocytes: Possible Relevance for the Immune Invasion of the Central Nervous System and the Pathogenesis of Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2002, 22, 631-640.	0.5	68
18	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro-Oncology, 2014, 16, 719-727.	0.6	68

#	Article	IF	CITATIONS
19	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 1994, 39, 193-197.	2.0	64
20	Lycopersicon esculentum lectin: an effective and versatile endothelial marker of normal and tumoral blood vessels in the central nervous system. European Journal of Histochemistry, 2004, 48, 423.	0.6	64
21	Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. Journal of Neuro-Oncology, 2004, 66, 203-208.	1.4	64
22	Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology, 1998, 82, 5-12.	1.1	59
23	Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. Journal of Neuro-Oncology, 2013, 113, 293-303.	1.4	59
24	Living with a brain tumor. Supportive Care in Cancer, 2013, 21, 1105-1111.	1.0	54
25	CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients. Journal of Neuro-Oncology, 2005, 74, 287-293.	1.4	53
26	The burden of brain tumor: a single-institution study on psychological patterns in caregivers. Journal of Neuro-Oncology, 2012, 107, 175-181.	1.4	51
27	Low serum interleukin-10 levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression?. Journal of Neurology, 1995, 243, 13-17.	1.8	49
28	Nestin, PDGFR-Î ² , CXCL12 and VEGF in gliomapatients: Different profiles of (Pro-Angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biology and Therapy, 2007, 6, 1018-1024.	1.5	49
29	New High-Performance Liquid Chromatographic Method for Plasma/Serum Analysis of Lamotrigine. Therapeutic Drug Monitoring, 2001, 23, 665-668.	1.0	48
30	Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. European Journal of Cancer, 2009, 45, 3315-3325.	1.3	48
31	Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2017, 135, 545-552.	1.4	48
32	Double-Blind Randomized Trial of ACTH versus Dexamethasone versus Methylprednisolone in Multiple Sclerosis Bouts. European Neurology, 1989, 29, 10-14.	0.6	47
33	The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia. PLoS Pathogens, 2014, 10, e1004167.	2.1	46
34	Lecture: fotemustine in brain tumors. Neurological Sciences, 2011, 32, 255-257.	0.9	45
35	Human Brain Endothelial Cells and Astrocytes Produce ILâ€1β but not ILâ€10. Scandinavian Journal of Immunology, 1996, 44, 506-511.	1.3	43
36	Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis. Archives of Neurology, 2002, 59, 774.	4.9	43

#	Article	IF	CITATIONS
37	A double blind study on azathioprine efficacy in multiple sclerosis: final report. Journal of Neurology, 1993, 240, 295-298.	1.8	42
38	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. Journal of Neuro-Oncology, 2008, 88, 105-113.	1.4	42
39	Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biology and Therapy, 2011, 11, 242-253.	1.5	41
40	Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome. A follow-up study. Neurological Sciences, 2000, 21, 157-164.	0.9	40
41	Effects of \hat{l}^2 -IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. Journal of Neuroimmunology, 1997, 79, 76-83.	1.1	39
42	Immunocompetence of human microvascular brain endothelial cells: cytokine regulation of IL- $1\hat{l}^2$, MCP-1, IL-10, sICAM-1 and sVCAM-1. Journal of Neurology, 1998, 245, 727-730.	1.8	39
43	Corticosteroids protect oligodendrocytes from cytokine-induced cell death. NeuroReport, 2000, 11, 3969-3972.	0.6	39
44	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. Journal of Neuro-Oncology, 2005, 72, 125-131.	1.4	39
45	COVIDâ€19 in dimethyl fumarateâ€treated patients with multiple sclerosis. Journal of Neurology, 2021, 268, 2023-2025.	1.8	39
46	Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clinical Chemistry and Laboratory Medicine, 2009, 47, 874-9.	1.4	38
47	Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. Journal of Neurology, 1993, 241, 96-100.	1.8	37
48	High-Dose Methylprednisolone Reduces Cytokine-Induced Adhesion Molecules on Human Brain Endothelium. Canadian Journal of Neurological Sciences, 2000, 27, 241-244.	0.3	37
49	Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences, 2007, 28, 304-310.	0.9	36
50	An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis. Multiple Sclerosis Journal, 1995, 1, 181-185.	1.4	35
51	Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biology and Therapy, 2006, 5, 827-832.	1.5	35
52	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. Journal of Neuro-Oncology, 2008, 87, 143-151.	1.4	35
53	In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 76.	3.5	33
54	Management of epilepsy in brain tumors. Neurological Sciences, 2019, 40, 2217-2234.	0.9	33

#	Article	IF	CITATIONS
55	Headache in brain tumours: a symptom to reappraise critically. Neurological Sciences, 2004, 25, s143-s147.	0.9	32
56	Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurological Sciences, 2006, 27, 345-351.	0.9	32
57	Quality of life and brain tumors: what beyond the clinical burden?. Journal of Neurology, 2014, 261, 894-904.	1.8	31
58	Modulation of Fas-Ligand (Fas-L) on human microglial cells: an in vitro study. Journal of Neuroimmunology, 2000, 105, 109-114.	1.1	30
59	Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurological Sciences, 2001, 22, 17-20.	0.9	30
60	Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. Neurological Sciences, 2008, 29, 131-137.	0.9	30
61	Glial dystrophin-associated proteins, laminin and agrin, are downregulated in the brain of mdx mouse. Laboratory Investigation, 2010, 90, 1645-1660.	1.7	30
62	Multidrug resistance proteins expression in glioma patients with epilepsy. Journal of Neuro-Oncology, 2012, 110, 129-135.	1.4	30
63	Strokeâ€like events after brain radiotherapy: a large series with longâ€term followâ€up. European Journal of Neurology, 2019, 26, 639-650.	1.7	29
64	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Italian Journal of Neurological Sciences, 1999, 20, 43-48.	0.1	26
65	MIG–differential gene expression in mouse brain endothelial cells. NeuroReport, 2002, 13, 9-14.	0.6	26
66	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. Neurological Sciences, 2002, 23, 219-224.	0.9	26
67	In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. Journal of Neuro-Oncology, 2005, 71, 19-25.	1.4	26
68	A spectrum of LMX1B mutations in Nail-Patella syndrome: New point mutations, deletion, and evidence of mosaicism in unaffected parents. Genetics in Medicine, 2010, 12, 431-439.	1.1	26
69	Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. Journal of Neurosurgery, 2013, 118, 821-829.	0.9	26
70	Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 554-557.	0.9	25
71	Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. Journal of Neuro-Oncology, 1997, 34, 179-185.	1.4	25
72	Modulation of ICAM-1, VCAM-1 and HLA-DR by cytokines and steroids on HUVECs and human brain endothelial cells. Journal of the Neurological Sciences, 1998, 157, 117-121.	0.3	25

#	Article	IF	CITATIONS
73	Chemotherapy is effective as early treatment for primary central nervous system lymphoma. Journal of Neurology, 1999, 246, 31-37.	1.8	25
74	Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. Journal of Neuro-Oncology, 2009, 94, 57-62.	1.4	25
75	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. Neurology, 2013, 81, 1014-1017.	1.5	25
76	Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis. Journal of Clinical		

#	Article	IF	CITATIONS
91	Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma. Journal of Neuro-Oncology, 2005, 75, 215-220.	1.4	20
92	Activation of cerebral endothelium is required for mononuclear cell recruitment in a novel in vitro model of brain inflammation. Neuroscience, 2006, 137, 1211-1219.	1.1	20
93	Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. Journal of Neuro-Oncology, 2012, 106, 595-600.	1.4	20
94	Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): A new report of an Italian woman and review of the literature. Journal of the Neurological Sciences, 2013, 326, 115-119.	0.3	20
95	Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines. Journal of Personalized Medicine, 2021, 11, 390.	1.1	20
96	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. Italian Journal of Neurological Sciences, 1994, 15, 333-340.	0.1	19
97	Successful Adoptive Immunotherapy with Lymphokine-activated Killer Cells in the Treatment of Medulloblastoma Disseminated via Cerebrospinal Fluid. Neurosurgery, 1994, 34, 1078-1080.	0.6	19
98	Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. Journal of Neuro-Oncology, 2003, 64, 193-201.	1.4	19
99	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. Journal of Neuro-Oncology, 2007, 82, 273-279.	1.4	19
100	A novel mutation in the GFAP gene in a familial adult onset Alexander disease. Journal of Neurology, 2007, 254, 1278-1280.	1.8	19
101	Increased migration of a human glioma cell line after in vitro CyberKnife irradiation. Cancer Biology and Therapy, 2011, 12, 629-633.	1.5	19
102	Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clinical and Experimental Rheumatology, 1994, 12, 389-94.	0.4	19
103	Immunological Alterations in Cluster Headache During Remission and Cluster Period. Comparison with Low Back Pain Patients. Cephalalgia, 1992, 12, 250-253.	1.8	18
104	Immunological Fluctuations During Intrathecal Immunotherapy in Three Patients Affected by CNS Tumours Disseminating Via CSF. International Journal of Neuroscience, 1994, 77, 117-125.	0.8	18
105	The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients. Journal of Neurology, 1994, 241, 615-619.	1.8	18
106	Effect of Association of Temozolomide With Other Chemotherapic Agents on Cell Growth Inhibition in Glioma Cell Lines. Oncology Research, 2004, 14, 325-330.	0.6	18
107	The Italian Registry of Endovascular Treatment in Acute Stroke: rationale, design and baseline features of patients. Neurological Sciences, 2015, 36, 985-993.	0.9	18
108	Biâ€hemispheric transcranial direct current stimulation for upperâ€limb hemiparesis in acute stroke: a randomized, doubleâ€blind, shamâ€controlled trial. European Journal of Neurology, 2020, 27, 2473-2482.	1.7	18

#	Article	IF	CITATIONS
109	Evidence of Linkage between Susceptibility to Multiple Sclerosis and HLA-Class II Loci in Italian Multiplex Families. European Journal of Human Genetics, 1995, 3, 303-311.	1.4	18
110	Immunoblotting techniques with picogram sensitivity in cerebrospinal fluid protein detection. Electrophoresis, 1989, 10, 34-40.	1.3	17
111	Local drug delivery in recurrent malignant gliomas. Neurological Sciences, 2005, 26, s37-s39.	0.9	17
112	Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurological Sciences, 2014, 35, 83-89.	0.9	17
113	Herpes simplex encephalitis in glioma patients: a challenging diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 374-377.	0.9	17
114	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 455-462.	1.4	17
115	Cryptococcal meningoencephalitis: intrathecal immunological response. Journal of Neurology, 1986, 233, 362-366.	1.8	16
116	Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results. Italian Journal of Neurological Sciences, 1988, 9, 53-57.	0.1	16
117	ANALYSIS OF HLA-CLASS II DQA1, DQB1, DRB1 and DPB1 IN ITALIAN MULTIPLE SCLEROSIS PATIENTS. International Journal of Immunogenetics, 1995, 22, 171-178.	1.2	16
118	Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Italian Journal of Neurological Sciences, 1998, 19, 32-36.	0.1	16
119	Immunological effects of in vivo interferon- \hat{l}^2 1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. Journal of Neurology, 1999, 246, 569-573.	1.8	16
120	Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurological Sciences, 2009, 30, 251-254.	0.9	16
121	Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine. Journal of Clinical Neuroscience, 2014, 21, 690-691.	0.8	16
122	SMART (stroke-like migraine attack after radiation therapy) syndrome: a case report with review of the literature. Neurological Sciences, 2016, 37, 157-161.	0.9	16
123	Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (<scp>TAR) Tj ETQq1 1 0.78431 <scp>C</scp>ys139<scp>A</scp>rg. Brain Pathology, 2018, 28, 72-76.</scp>	.4 rgBT /O 2.1	verlock 10 T 16
124	Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients. Journal of the Neurological Sciences, 2019, 400, 175-179.	0.3	16
125	Valproic Acid Increases the In Vitro Effects of Nitrosureas on Human Glioma Cell Lines. Oncology Research, 2007, 16, 453-463.	0.6	15
126	Decrease in circulating endothelial progenitor cells in treated glioma patients. Journal of Neuro-Oncology, 2012, 108, 123-129.	1.4	15

#	Article	IF	CITATIONS
127	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. Journal of Neurosurgical Sciences, 2020, 64, 313-334.	0.3	15
128	Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity. Journal of Neurology, 1993, 240, 79-82.	1.8	14
129	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. Cancer Chemotherapy and Pharmacology, 1999, 43, 178-179.	1.1	14
130	Tumor Necrosis Factor Microsatellite Polymorphisms in Italian Glioblastoma Patients. Cancer Genetics and Cytogenetics, 1999, 109, 172-174.	1.0	14
131	Meningitis following relapsing painful ophthalmoplegia in aspergillus sphenoidal sinusitis: a case report. Neurological Sciences, 2006, 27, 284-287.	0.9	14
132	Brain metastases in patients receiving trastuzumab for breast cancer. Neurological Sciences, 2007, 28, 1-1.	0.9	14
133	CSF T-cell subsets in multiple sclerosis: Relationship to cerebrospinal fluid myelin basic protein and clinical activity. Journal of Neurology, 1989, 236, 336-339.	1.8	13
134	HLA antigens in Italian multiple sclerosis patients. Italian Journal of Neurological Sciences, 1991, 12, 81-86.	0.1	13
135	Late-Onset Triple A Syndrome: A Risk of Overlooked or Delayed Diagnosis and Management. Hormone Research in Paediatrics, 2008, 70, 364-372.	0.8	13
136	Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurological Sciences, 2013, 34, 2151-2157.	0.9	13
137	Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment. Journal of the Neurological Sciences, 2014, 336, 169-170.	0.3	13
138	Melanoma Cells Homing to the Brain: An <i>In Vitro</i> Model. BioMed Research International, 2015, 2015, 1-11.	0.9	13
139	Donepezil modulates the endogenous immune response: implications for Alzheimer's disease. Human Psychopharmacology, 2016, 31, 296-303.	0.7	13
140	Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals. Journal of the Neurological Sciences, 2017, 378, 3-8.	0.3	13
141	Polymethyl Methacrylate Cranioplasty Is an Effective Ultrasound Window to Explore Intracranial Structures: Preliminary Experience and Future Perspectives. World Neurosurgery, 2019, 127, e1013-e1019.	0.7	13
142	Stressful life events and multiple sclerosis: a retrospective study. Italian Journal of Neurological Sciences, 1998, 19, 259-260.	0.1	12
143	A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy. Neurological Sciences, 2005, 26, 227-234.	0.9	12
144	A case of late herpes simplex encephalitis relapse. Journal of Clinical Virology, 2013, 58, 269-270.	1.6	12

#	Article	IF	Citations
145	High-Dose Methylprednisolone Treatment-Induced Changes in Immunological Parameters in Progressive Ms Patients. International Journal of Neuroscience, 1994, 75, 119-128.	0.8	11
146	IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings. Italian Journal of Neurological Sciences, 1997, 18, 191-194.	0.1	11
147	In Vitro Modulation of Adhesion Molecules, Adhesion Phenomena, and Fluid Phase Endocytosis on Human Umbilical Vein Endothelial Cells and Brain-Derived Microvascular Endothelium by IFN- \hat{l}^2 1a. Journal of Interferon and Cytokine Research, 2001, 21, 267-272.	0.5	11
148	Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results. Acta Neurologica Scandinavica, 1997, 96, 283-292.	1.0	11
149	Muscle ultrasonography for detecting fasciculations in frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 546-550.	1.1	11
150	Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma. Neurological Sciences, 2015, 36, 1501-1503.	0.9	11
151	Reducing time delays in the management of ischemic stroke patients in Northern Italy. International Journal of Cardiology, 2016, 215, 431-434.	0.8	11
152	Psychological features and quality of life in 50 adult patients with epilepsy and their caregivers from the Lecco epilepsy center, Italy. Epilepsy and Behavior, 2017, 71, 13-16.	0.9	11
153	HSV-1 encephalitis relapse after epilepsy surgery: a case report and review of the literature. Journal of NeuroVirology, 2020, 26, 138-141.	1.0	11
154	Reduction of transendothelial migration of mononuclear cells in interferon-?1b-treated multiple sclerosis patients. Annals of Neurology, 1999, 46, 435-435.	2.8	10
155	An Italian family with Nasu-Hakola disease. Journal of Neurology, 2003, 250, 878-880.	1.8	10
156	Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. Journal of Neuro-Oncology, 2011, 104, 617-618.	1.4	10
157	Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. Journal of Neuroimmunology, 2016, 290, 119-122.	1.1	10
158	Outcome in lacunar stroke: A cohort study. Acta Neurologica Scandinavica, 2018, 138, 320-326.	1.0	10
159	The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study. Epilepsy and Behavior, 2020, 102, 106641.	0.9	10
160	HLA and multiple sclerosis in Italy: a review of the literature. Journal of Neurology, 1990, 237, 441-444.	1.8	9
161	TUMOUR NECROSIS FACTOR MICROSATELLITE ALLELES IN AN ITALIAN POPULATION. International Journal of Immunogenetics, 1997, 24, 9-13.	1.2	9
162	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. Journal of Neuro-Oncology, 2000, 49, 71-75.	1.4	9

#	Article	IF	CITATIONS
163	Embryonal tumors in the adult population: implications in therapeutic planning. Neurological Sciences, 2000, 21, 23-30.	0.9	9
164	Modulation of Experimental Allergic Encephalomyelitis in Lewis Rats by Administration of a Peptide of Fas Ligand. Journal of Autoimmunity, 2001, 17, 273-280.	3.0	9
165	Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. Neurological Sciences, 2002, 23, 257-258.	0.9	9
166	Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunology, Immunotherapy, 2004, 53, 955-962.	2.0	9
167	Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. Cancer Biology and Therapy, 2006, 5, 204-209.	1.5	9
168	Intracerebral haemorrhage in primary and metastatic brain tumours. Neurological Sciences, 2008, 29, 264-265.	0.9	9
169	In vitro effects of Cyberknife-driven intermittent irradiation on glioblastoma cell lines. Neurological Sciences, 2011, 32, 579-588.	0.9	9
170	Operability of glioblastomas: "sins of action―versus "sins of non-action― Neurological Sciences, 2013, 34, 2107-2116.	0.9	9
171	Isolated acute dysphagia due to varicella-zoster virus. Journal of Clinical Virology, 2014, 59, 268-269.	1.6	9
172	MR-Spectroscopy and Survival in Mice with High Grade Glioma Undergoing Unrestricted Ketogenic Diet. Nutrition and Cancer, 2021, 73, 2315-2322.	0.9	9
173	Cerebral venous thrombosis associated with coronavirus infection: an underestimated entity?. Neurological Sciences, 2021, 42, 317-318.	0.9	9
174	Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 413-414.	0.9	9
175	Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment?. Annals of Neurology, 2000, 47, 137-8.	2.8	9
176	Immunoblotting on polyvinyldifluoride improves detection of oligoclonal IgG bands in CSF Clinical Chemistry, 1987, 33, 1669-1670.	1.5	8
177	Analysis of peripheral blood lymphocyte phenotype and function during dexamethazone treatment of progressive multiple sclerosis. Acta Neurologica Scandinavica, 1991, 84, 91-97.	1.0	8
178	Remarkable Recovery of Visual Function in a Patient with Leber's Optic Neuropathy and Multiple Mutations of Mitochondrial DNA. International Journal of Neuroscience, 1994, 77, 261-266.	0.8	8
179	Parallel fluctuations of psychiatric and neurological symptoms in a patient with multiple sclerosis and bipolar affective disorder. Italian Journal of Neurological Sciences, 1995, 16, 551-553.	0.1	8
180	Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature. Italian Journal of Neurological Sciences, 1996, 17, 135-139.	0.1	8

#	Article	IF	Citations
181	Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients. Journal of Neuroimmunology, 1998, 87, 88-93.	1.1	8
182	Radiotherapy at tumor recurrence in primary CNS lymphoma. Neurology, 1998, 50, 1934-1935.	1.5	8
183	In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena. Annals of Neurology, 2000, 47, 680-681.	2.8	8
184	Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience. Neurological Sciences, 2008, 29, 77-83.	0.9	8
185	Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. Strahlentherapie Und Onkologie, 2013, 189, 456-461.	1.0	8
186	Caring for Brain Tumour Patients: Psychological Reactions After Bereavement. Journal of Palliative Care, 2015, 31, 97-102.	0.4	8
187	Brainstem glioblastoma in a patient with secondary progressive multiple sclerosis. Neurological Sciences, 2015, 36, 1733-1735.	0.9	8
188	Immunological Monitoring and Clinical Evaluation in Cyclophosphamide-Treated Progressive Multiple Sclerosis Patients. International Journal of Neuroscience, 1994, 76, 305-312.	0.8	7
189	Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients. Journal of the Neurological Sciences, 2018, 390, 14-19.	0.3	7
190	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 1994, 39, 193-197.	2.0	7
191	Neurocysticercosis: Clinical and therapeutic considerations. Review of italian literature. Italian Journal of Neurological Sciences, 1986, 7, 525-529.	0.1	6
192	Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurological Sciences, 2003, 24, 272-272.	0.9	6
193	Voluptuary Habits and Risk of Frontotemporal Dementia: A Case Control Retrospective Study. Journal of Alzheimer's Disease, 2017, 60, 335-340.	1.2	6
194	NIHSS as predictor of clinical outcome at 6Âmonths in patients with intracerebral hemorrhage. Neurological Sciences, 2020, 41, 717-719.	0.9	6
195	Concomitant cerebral aspergillosis and mucormycosis in an immunocompetent woman treated with corticosteroids. Journal of NeuroVirology, 2020, 26, 277-280.	1.0	6
196	INTRATHECAL BETA-INTERFERON IN MULTIPLE SCLEROSIS. Lancet, The, 1988, 332, 563-564.	6.3	5
197	Short term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment. Italian Journal of Neurological Sciences, 1992, 13, 107-112.	0.1	5
198	Physical Effort-Induced Changes in Immune Parameters. International Journal of Neuroscience, 1993, 68, 133-140.	0.8	5

#	Article	IF	Citations
199	Eugenio Tanzi (1856–1934) and the beginnings of European neurology. Journal of the History of the Neurosciences, 1994, 3, 177-185.	0.1	5
200	Prosopagnosia. Current Opinion in Neurology, 1994, 7, 61-64.	1.8	5
201	Familial intracranial hypertension: a case report. Italian Journal of Neurological Sciences, 1996, 17, 167-168.	0.1	5
202	Long-term immunological changes in azathioprine-treated MS patients. Neurological Sciences, 2000, 21, 87-91.	0.9	5
203	Bevacizumab at recurrence in high-grade glioma. Neurological Sciences, 2011, 32, 251-253.	0.9	5
204	A case of Bing–Neel syndrome presenting as spinal cord compression. Journal of the Neurological Sciences, 2014, 346, 345-347.	0.3	5
205	Efficacy of high dose methylprednisolone in a patient with cervical dystonia and blepharospasm and Sjögren's syndrome. Neurological Sciences, 2015, 36, 803-804.	0.9	5
206	A case of papilloedema associated with Chiari I malformation. Journal of the Neurological Sciences, 2015, 353, 183-184.	0.3	5
207	Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian) Tj ETQq1 1 0.7843142, 665-671.	.4 rgBT /O 0.9	verlock 10° 5
208	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. Neurological Sciences, 2021, 42, 1879-1886.	0.9	5
209	Magnetic resonance imaging in multiple sclerosis: Diagnostic value and clinical correlations. Italian Journal of Neurological Sciences, 1988, 9, 127-134.	0.1	4
210	Monocyte phenotype in blood and cerebrospinal fluid: Compartment-specific pattern is unrelated to neurological disease. Journal of the Neurological Sciences, 1993, 120, 201-207.	0.3	4
211	Phenotype analysis of unstimulated lymphocytes and anti-cd3-stimulated proliferating t-cells from cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and other neurological diseases. International Journal of Neuroscience, 1993, 73, 277-285.	0.8	4
212	Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules. Italian Journal of Neurological Sciences, 1996, 17, 267-276.	0.1	4
213	CFS Oligoclonal bands in MS and other neurological diseases detected by agarose isoelectric focusing and electrophoresis. Italian Journal of Neurological Sciences, 1984, 5, 303-310.	0.1	3
214	Role of Physical Training on Immune Function: Preliminary Data. International Journal of Neuroscience, 1990, 51, 249-252.	0.8	3
215	Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience. Journal of Neuro-Oncology, 2013, 113, 527-529.	1.4	3
216	Neoplastic Meningitis from Solid Tumors: A Prospective Clinical Study in Lombardia and a Literature Review on Therapeutic Approaches. Journal of Drug Delivery, 2013, 2013, 1-6.	2.5	3

#	Article	IF	CITATIONS
217	Pitfall in neurology: giant cell arteritis mimicking ocular myasthenia gravis. Neurological Sciences, 2015, 36, 665-666.	0.9	3
218	Headache in cerebral venous thrombosis associated with extracranial tumors: a clinical series. Neurological Sciences, 2015, 36, 149-151.	0.9	3
219	Genetic Counseling Dilemmas for a Patient with Sporadic Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration & Parkinson's Disease. Journal of Genetic Counseling, 2017, 26, 442-446.	0.9	3
220	Short Course Radiotherapy Concomitant with Temozolomide in GBM Patients: A Phase II Study. Tumori, 2017, 103, 457-463.	0.6	3
221	Bilateral Radiation-Induced Hypoglossal Nerve Palsy Responsive to Steroid Treatment. Journal of		

#	Article	IF	Citations
235	Pravastatin in vivo reduces mononuclear cell migration through endothelial monolayers. Neurological Sciences, 2006, 27, 261-265.	0.9	1
236	Progressive myoclonic ataxia with intrathecal immune activation in six patients. Neurological Sciences, 2007, 28, 199-204.	0.9	1
237	Involvement of the CXCL12/CXCR4/CXCR7 Axis in Brain Metastases. , 2014, , 25-36.		1
238	Stroke severity and outcome in women and men in the Lecco area, Italy. European Journal of Internal Medicine, 2014, 25, e50-e51.	1.0	1
239	Pathophysiology of Brain Tumor-Related Epilepsy. , 2015, , 111-118.		1
240	A case of recurrent stroke due to late onset antiphospholipid syndrome. Neurological Sciences, 2017, 38, 2221-2222.	0.9	1
241	Novel Lys215Asn mutation in an Italian family with Thomsen myotonia. Neurological Sciences, 2018, 39, 1491-1492.	0.9	1
242	Intrathecal immune activation in a case of progressive action myoclonus. Functional Neurology, 1988, 3, 105-13.	1.3	1
243	New trends in the management of primary cerebral non-Hodgkin's lymphoma (PCNSL). Italian Journal of Neurological Sciences, 1998, 19, 53-54.	0.1	0
244	The role of the neurologist. Neurological Sciences, 2005, 26, s46-s48.	0.9	0
245	Commentary on "Expression of dopamine 2 receptor subtypes mRNA in clinically nonfunctioning pituitary adenomas― Neurological Sciences, 2012, 33, 281-281.	0.9	O
246	Autoimmunity meets genetics: Multiple sclerosis in a patient with Kallmann syndrome. Journal of the Neurological Sciences, 2016, 367, 256-257.	0.3	0
247	Tumor like reversible seizure-induced brain MRI abnormalities in a patient previously treated for Nocardia brain abscess. An avoided clinical pitfall. Neurological Sciences, 2017, 38, 373-374.	0.9	O
248	A case of unusually long survival after leptomeningeal carcinomatosis diagnosis. Journal of Neuro-Oncology, 2018, 137, 215-218.	1.4	0
249	In Reply to the Letter to the Editor Regarding "Polymethyl-Methacrylate Cranioplasty Is an Effective Ultrasound Window to Explore Intracranial Structures: Preliminary Experience and Future Perspectives― World Neurosurgery, 2019, 129, 548.	0.7	0
250	In Reply to "Application of Transcranial Sonography in Post-Cranioplasty― World Neurosurgery, 2019, 128, 638.	0.7	0